ARVN logo

ARVINAS INC

ARVNNASDAQ
🏆 #2981 by market capEarnings Nov 3US Equity
$1,007.41▼ $75.86 (−7.53%)
Simulated price
🔔
Track ARVN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$496M
Small Cap
📈Revenue Growth (YoY)
-15.1%
Declining
📊Gross Margin
—
💵FCF Margin
15.7%
Healthy
⚖️P/S Ratio
1.6x
Cheap
Otter Score
88
Very Good
No chart data available for ARVN.

Trading Snapshot

Day Range
$1,002.08 – $1,019.18
52-Week Range
$6.97 – $14.51
Volume
$2.77B
Avg Volume
$2.69B
Shares Outstanding
64.5M
Next Earnings
Nov 22, 2026

Fundamentals Snapshot

Annual Revenue
$263M
Last Q Revenue
$250M
P/E Ratio
53.4
P/S Ratio
1.6x
EPS (TTM)
$0.16
Dividend Yield
—
Dilution (1yr)
−10.0%

Why Investors Own ARVN

  • ✓High-growth profile — revenue up +26.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 70% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ARVN logo

ARVINAS INC

ARVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$263M▼ −0.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
98.0%▼ −2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$115M▼ −54.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$276M▲ +5.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.9M▼ −10.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$134M▲ +$43M YoY
StockOtter · stockotter.space

About ARVINAS INC

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$1,185.18
▲ +17.6% Upside
High Target$1,343.74
Low Target$1,093.16
Based on 11 analysts

Latest News & Updates

🚀
CNBC·2h ago

ARVINAS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift ARVN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ARVINAS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.